Evaluation of immunization rates and safety among children with inborn errors of metabolism

Nicola P Klein1, Laurie Aukes, Janelle Lee

  • 1Kaiser Permanente Vaccine Study Center, 1 Kaiser Plaza, 16th Floor, Oakland, CA 94612, USA. nicola.klein@kp.org

Pediatrics
|April 13, 2011
PubMed

Insights

Children with inborn errors of metabolism (IEM) receive routine vaccines on schedule and without increased risk of adverse events. This study provides reassurance for vaccinating this vulnerable pediatric population against preventable diseases.

Area of Science:

  • Pediatric immunology
  • Metabolic disorders
  • Vaccinology

Background:

  • Children with inherited metabolic disorders (IMDs) are at higher risk for vaccine-preventable diseases.
  • Limited data exist on immunization rates and vaccine safety in children with IMDs.

Purpose of the Study:

  • To assess immunization rates in infants with inborn errors of metabolism (IEM).
  • To evaluate vaccine safety in children with IEM.

Main Methods:

  • Retrospective electronic health record review of children with IEM (1990-2007) at Northern California Kaiser Permanente.
  • Comparison of immunization status and age at vaccination with matched healthy controls.
  • Assessment of post-vaccination adverse events (emergency department visits, hospitalizations) within 30 days.

Main Results:

  • Infants with IEM had similar vaccination rates by age 2 and no delay in vaccine receipt compared to controls.
  • Vaccination was not associated with increased emergency department visits or hospitalizations within 30 days post-vaccination.
  • A potential increase in hospitalizations was noted within 2 weeks for the sickest children aged 1-4 years.

Conclusions:

  • Children with IEM follow the same immunization schedule as healthy children.
  • Routine vaccination of children with IEM is safe and not associated with increased serious adverse events.
  • Findings offer reassurance for the vaccination of children with IEM against preventable diseases.
Abstract

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...